首页> 美国卫生研究院文献>Microbial Cell Factories >High cell density cultivation of Escherichia coli K4 in a microfiltration bioreactor: a step towards improvement of chondroitin precursor production
【2h】

High cell density cultivation of Escherichia coli K4 in a microfiltration bioreactor: a step towards improvement of chondroitin precursor production

机译:在微滤生物反应器中高细胞密度培养大肠杆菌K4:迈向改善软骨素前体生产的一步

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundThe bacteria Escherichia coli K4 produces a capsular polysaccharide (K4 CPS) whose backbone is similar to the non sulphated chondroitin chain. The chondroitin sulphate is one of the major components of the extra-cellular matrix of the vertebrate connective tissues and a high value molecule, widely employed as active principle in the treatment of osteoarthritis. It is usually obtained by extraction from animal tissues, but the risk of virus contaminations, as well as the scarceness of raw material, makes this productive process unsafe and unable to satisfy the growing market demand. In previous studies a new biotechnological process to produce chondroitin from Escherichia coli K4 capsular polysaccharide was investigated and a 1.4 g·L-1 K4 CPS concentration was reached using fed-batch fermentation techniques. In this work, on the trail of these results, we exploited new fermentation strategies to further improve the capsular polysaccharide production.
机译:背景细菌大肠杆菌K4产生荚膜多糖(K4 CPS),其骨架类似于非硫酸化软骨素链。硫酸软骨素是脊椎动物结缔组织细胞外基质的主要成分之一,是一种高价值分子,被广泛用作治疗骨关节炎的有效成分。它通常是通过从动物组织中提取获得的,但是病毒污染的风险以及原材料的稀缺性使得该生产过程不安全,无法满足不断增长的市场需求。在以前的研究中,研究了一种从大肠杆菌K4荚膜多糖生产软骨素的新生物技术工艺,并使用分批补料发酵技术将其浓度提高到1.4 g·L -1 K4 CPS。在这项工作中,根据这些结果,我们开发了新的发酵策略来进一步改善荚膜多糖的生产。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号